Change in leadership at Allergopharma GmbH & Co. KG

  • Philipp Maerz new CEO as of March 1, 2019 at Allergopharma
  • Marco Linari will return to Merck Darmstadt
Reinbek, 28 February 2019 – Allergopharma, the allergy business of Merck, will be under new leadership from March 1, 2019. Marco Linari who led the company for five years as Chief Executive Officer (CEO), will hand over to Philipp Maerz effective March 1, 2019 and assumes a new role within the Merck Group.

Philipp Maerz joined Allergopharma at the beginning of 2013 as Vice President Business Development, Strategy & International Business of Merck and has been Chief Operating Officer (COO) since May 2016.

Marco Linari who joined Merck in 2004, has been CEO of Allergopharma since 2014 and has driven the company's change process with passion and commitment to further modernize Allergopharma.

“We have already achieved a lot in terms of strategic realignment for Allergopharma,” explains Philipp Maerz. “In a difficult market environment and in the year of our 50th anniversary, we will continue to expand our strengths: we aim to continuously position our new brand in the allergy market. Moreover, we are planning extensive investments in our modern production, digitization and clinical studies, and we are driving forward the development of our products with these investments”.
About Allergopharma

Allergopharma GmbH & Co. KG, the allergy business of Merck, is one of the leading companies for allergen immunotherapy (AIT), celebrating its 50th anniversary in 2019.
The product portfolio includes: allergen immunotherapy (AIT) of type I allergies such as allergic rhinitis (e.g. hay fever) and allergic asthma, diagnostics and prevention. With many years of expertise, scientific excellence and corporate responsibility, more than 500 employees worldwide work to provide physicians with first-class treatment options and enable people with allergies to live a fulfilling life.
The products of Allergopharma are available in more than 18 countries worldwide. All products are manufactured in Reinbek near Hamburg, under ultra-clean, sterile conditions.


All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck

Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 51,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – Merck is everywhere. In 2017, Merck generated sales of € 15.3 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.

  • Philipp Maerz new CEO as of March 1, 2019 at Allergopharma
  • Marco Linari will return to Merck Darmstadt

Reinbek, 28 February 2019 – Allergopharma, the allergy business of Merck, will be under new leadership from March 1, 2019. Marco Linari who led the company for five years as Chief Executive Officer (CEO), will hand over to Philipp Maerz effective March 1, 2019 and assumes a new role within the Merck Group.

Philipp Maerz joined Allergopharma at the beginning of 2013 as Vice President Business Development, Strategy & International Business of Merck and has been Chief Operating Officer (COO) since May 2016.

Marco Linari who joined Merck in 2004, has been CEO of Allergopharma since 2014 and has driven the company's change process with passion and commitment to further modernize Allergopharma.

“We have already achieved a lot in terms of strategic realignment for Allergopharma,” explains Philipp Maerz. “In a difficult market environment and in the year of our 50th anniversary, we will continue to expand our strengths: we aim to continuously position our new brand in the allergy market. Moreover, we are planning extensive investments in our modern production, digitization and clinical studies, and we are driving forward the development of our products with these investments”.


About Allergopharma

Allergopharma GmbH & Co. KG, the allergy business of Merck, is one of the leading companies for allergen immunotherapy (AIT), celebrating its 50th anniversary in 2019.
The product portfolio includes: allergen immunotherapy (AIT) of type I allergies such as allergic rhinitis (e.g. hay fever) and allergic asthma, diagnostics and prevention. With many years of expertise, scientific excellence and corporate responsibility, more than 500 employees worldwide work to provide physicians with first-class treatment options and enable people with allergies to live a fulfilling life.
The products of Allergopharma are available in more than 18 countries worldwide. All products are manufactured in Reinbek near Hamburg, under ultra-clean, sterile conditions.


All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck

Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 51,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – Merck is everywhere. In 2017, Merck generated sales of € 15.3 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.


Service Downloads


Cooperations, Sponsorships & Partnerships